Literature DB >> 26247451

Outcomes of Pars Plana Vitrectomy for Patients With Vitreomacular Traction.

Marco A Gonzalez, Harry W Flynn, Christine L Bokman, William Feuer, William E Smiddy.   

Abstract

BACKGROUND AND
OBJECTIVE: To evaluate clinical and optical coherence tomography (OCT) outcomes of pars plana vitrectomy (PPV) for patients with vitreomacular traction (VMT). PATIENTS AND METHODS: Noncomparative, interventional, consecutive case series from 2007 to 2014.
RESULTS: Of the 37 study eyes, patients were grouped according to the extent of VMT evident on OCT. Group 1 (18 eyes) had intraretinal cysts on OCT. Group 2 (19 eyes) had both intraretinal cysts and subretinal fluid. Visual acuity (VA) improved at least one line or more in 76% of eyes postoperatively. Postoperative VA was not significantly different across the two groups (P > .36). Postoperatively, a macular hole developed in 4 eyes (10%). After reoperation, three of four eyes achieved macular hole closure.
CONCLUSIONS: Patients with VMT achieve visual and OCT improvements after PPV. Postoperative macular hole formation is uncommon but can be successfully repaired with further surgery. Copyright 2015, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26247451     DOI: 10.3928/23258160-20150730-04

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  3 in total

1.  The Charles Schepens Lecture: Management Options for Vitreomacular Traction: Use an Individualized Approach.

Authors:  Harry W Flynn; Nidhi Relhan
Journal:  Ophthalmol Retina       Date:  2017 Jan-Feb

2.  Role of Tractional Forces and Internal Limiting Membrane in Macular Hole Formation: Insights from Intraoperative Optical Coherence Tomography.

Authors:  Elad Moisseiev; Glenn Yiu
Journal:  Case Rep Ophthalmol       Date:  2016-07-21

3.  Indications and outcomes for intravitreal injection of C3F8 gas for symptomatic vitreomacular traction.

Authors:  Josef Guber; Celine Rusch; Ivo Guber; Hendrik P N Scholl; Christophe Valmaggia
Journal:  Sci Rep       Date:  2021-09-10       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.